Abstract:Background The expression of Coiled-Coil Domain Containing 134(CCDC134) is up-regulated in different pan-cancer species. However, its prognostic value and correlation with immune infiltration in breast cancer are unclear. Therefore, we evaluated the prognostic role of CCDC134 in breast cancer and its correlation with immune invasion. Methods We downloaded the transcription profile of CCDC134 between breast cancer and normal tissues from the Cancer Genome Atlas (TCGA). CCDC134 protein expression was assessed by the Clinical Proteomic Cancer Analysis Consortium (CPTAC) and the Human Protein Atlas. Gene set enrichment analysis (GSEA) was also used for pathway analysis. Receiver operating characteristic (ROC) curve was used to differentiate breast cancer from adjacent normal tissues. Kaplan-Meier method was used to evaluate the effect of CCDC134 on survival rate. The protein-protein interaction (PPI) network is built from STRING. Function expansion analysis is performed using the ClusterProfiler package. Through tumor Immune Estimation Resource (TIMER) and tumor Immune System Interaction database (TISIDB) to determine the relationship between CCDC134 expression level and immune infiltration. CTD database is used to predict drugs that inhibit CCDC134 and PubChem database is used to determine the molecular structure of identified drugs. Results The expression of CCDC134 in breast cancer tissues was significantly higher than that of CCDC134 mRNA expression in adjacent normal tissues. ROC curve analysis showed that the AUC value of CCDC134 was 0.663. Kaplan-meier survival analysis showed that patients with high CCDC134 had a lower prognosis (57.27 months vs 36.96 months, P = 2.0E-6). Correlation analysis showed that CCDC134 mRNA expression was associated with tumor purity immune invasion. In addition, CTD database analysis identified abrine, Benzo ( A) Pyrene, bisphenol A, Soman, Sunitinib, Tetrachloroethylene, Valproic Acid as seven targeted therapy drugs that may be effective treatments for seven targeted therapeutics. It may be an effective treatment for inhibiting CCDC134. Conclusion In breast cancer, upregulated CCDC134 is significantly associated with lower survival and immune infiltrates invasion. Our study suggests that CCDC134 can serve as a biomarker of poor prognosis and a potential immunotherapy target in breast cancer. Seven drugs with significant potential to inhibit CCDC134 were identified.

TBP activates DCBLD1 transcription to promote cell cycle progression in cervical cancer

CCDC50, an Essential Driver Involved in Tumorigenesis, is a Potential Severity Marker of Diffuse Large B Cell Lymphoma

Lactylation stabilizes DCBLD1 activating the pentose phosphate pathway to promote cervical cancer progression

TBC1D10B Promotes Tumor Progression in Colon Cancer Via PAK4‑mediated Promotion of the PI3K/AKT/mTOR Pathway.

Transducin (Β)-Like 1 X-linked Receptor 1 Promotes Proliferation and Tumorigenicity in Human Breast Cancer Via Activation of Beta-Catenin Signaling

CCDC134 as a Prognostic-Related Biomarker in Breast Cancer Correlating With Immune Infiltrates

Association of DCBLD2 Upregulation with Tumor Progression and Poor Survival in Colorectal Cancer

Circ‐DTL sponges miR‐758‐3p to accelerate cervical cancer malignant progression by regulating DCUN1D1 expression

CCNB1 is involved in bladder cancer pathogenesis and silencing CCNB1 decelerates tumor growth and improves prognosis of bladder cancer

Accumulation of Dysfunctional Tumor-Infiltrating PD-1+ DCs Links PD-1/PD-L1 Blockade Immunotherapeutic Response in Cervical Cancer

Activation of the G Protein-Coupled Bile Acid Receptor TGR5 Modulates the HCP5/miR-139-5p/DDIT4 Axis to Antagonize Cervical Cancer Progression

BICD1 functions as a prognostic biomarker and promotes hepatocellular carcinoma progression

Overexpression of DBC1, Correlated with Poor Prognosis, is a Potential Therapeutic Target for Hepatocellular Carcinoma.

Aberrant expression of TCTP protein inhibits cell apoptosis by up-regulating Bcl-xL in human pancreatic cancer

CCNB1 Expedites the Progression of Cervical Squamous Cell Carcinoma via the Regulation by FOXM1

TBL1XR1 Induces Cell Proliferation and Inhibit Cell Apoptosis by the PI3K/AKT Pathway in Pancreatic Ductal Adenocarcinoma.

Transcriptomic Profiling Identifies DCBLD2 As a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.

Translationally Controlled Tumor Protein Induces Mitotic Defects and Chromosome Missegregation in Hepatocellular Carcinoma Development

SHCBP1 Contributes to the Proliferation and Self‑renewal of Cervical Cancer Cells and Activation of the NF‑κB Signaling Pathway Through EIF5A.

C-terminal Binding Protein-2 Promotes Cell Proliferation and Migration in Breast Cancer Via Suppression of P16ink4a

DAX1 Promotes Cervical Cancer Cell Growth and Tumorigenicity Through Activation of Wnt/β-catenin Pathway Via GSK3β.